Waldencast’s Obagi sale creates a debt-free Milk Makeup pure play trading at a steep discount to its clean beauty brand value, but execution, leadership transition, and single-brand concentration remain the key tests.
Overview
Waldencast is transforming from a leveraged two-brand beauty consolidator into a debt-free, pure-play Milk Makeup platform through the planned sale of Obagi Medical to Bridgepoint for up to $460 million. Proceeds are expected to repay the $178 million term loan and leave meaningful net cash. The remaining business centers on Milk Makeup’s clean, vegan, culturally relevant prestige cosmetics franchise. The thesis is a structural reset: simplified operations, removed debt overhang, and a public market valuation that appears deeply discounted versus Milk’s standalone sales and EBITDA.